ArticleRambam Maimonides medical journal2014
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.
Article in Rambam Maimonides medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.Stem cell reviews and reports · 2025Pooled it
- MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines.Journal of inherited metabolic disease · 2021Guideline
- Total Body Irradiation and Risk of Diabetes Mellitus; A Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2019Pooled it
- Assessment of Neutrophil Chemotaxis Upon G-CSF Treatment of Healthy Stem Cell Donors and in Allogeneic Transplant Recipients.Frontiers in immunology · 2018Trial
- Fucosylation enhances CD34⁺ hematopoietic stem cell homing and longevity via E-selectin-mediated adhesion and signaling.BMC cancer · 2026Article
- Longitudinal plasma proteome profiling after allogeneic hematopoietic stem cell transplantation: heterogeneous development and associations with acute GvHD.Frontiers in immunology · 2026Article
- Tissue regenerative medicine: Clinical advances, challenges, and opportunities.APL bioengineering · 2025Article
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.Blood neoplasia · 2025Article
- Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers.Bone marrow transplantation · 2025Article
- Reduced incidence of relapse and graft-Haematologica · 2025Article
- Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Pharmacological modulation of stem cells signaling pathway for therapeutic applications.Stem cell research & therapy · 2025Review
- Intra-apheresis Cycling to Improve the Clinical Efficacy of Peripheral Blood Stem Cell Donations.Sports medicine (Auckland, N.Z.) · 2025Review
- Preparedness, Uncertainty, and Distress Among Family Caregivers in the Care of Patients Undergoing Hematopoietic Stem Cell Transplantation.Oncology nursing forum · 2025Article
- Factors affecting pretransplant muscle strength in allogeneic stem cell transplant candidates prior transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The Lived Experience of Adult Cancer Survivors After Hematopoietic Stem Cell Transplantation: A Qualitative Study From Saudi Arabia.Patient preference and adherence · 2025Article
- Cell therapies for immune-mediated disorders.Frontiers in medicine · 2025Review
- How Early Is Too Early? Use of Lineage-Specific Chimerism in Early Detection of Donor-Derived Malignancy After Allogeneic Stem Cell Transplant: A Case Report.Case reports in hematology · 2025Article
- Bloodstream infections epidemiology and clinical outcomes after 1 year post allogeneic hematogenous stem cell transplantation.Frontiers in microbiology · 2025Article
- Immune composition of the mononuclear cell fraction of human umbilical cord blood.Frontiers in immunology · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell transplantation is a highly specialized and unique medical procedure. Autologous transplantation allows the administration of high-dose chemotherapy without prolonged bone marrow aplasia. In allogeneic transplantation, donor-derived stem cells provide alloimmunity that enables a graft-versus-tumor effect to eradicate residual disease and prevent relapse. The first allogeneic transplantation was performed by E. Donnall Thomas in 1957. Since then the field has evolved and expanded worldwide. New indications beside acute leukemia and aplastic anemia have been constantly explored and now include congenital disorders of the hematopoietic system, metabolic disorders, and autoimmune disease. The use of matched unrelated donors, umbilical cord blood units, and partially matched related donors has dramatically extended the availability of allogeneic transplantation. Transplant-related mortality has decreased due to improved supportive care, including better strategies to prevent severe infections and with the incorporation of reduced-intensity conditioning protocols that lowered the toxicity and allowed for transplantation in older patients. However, disease relapse and graft-versus-host disease remain the two major causes of mortality with unsatisfactory progress. Intense research aiming to improve adoptive immunotherapy and increase graft-versus-leukemia response while decreasing graft-versus-host response might bring the next breakthrough in allogeneic transplantation. Strategies of graft manipulation, tumor-associated antigen vaccinations, monoclonal antibodies, and adoptive cellular immunotherapy have already proved clinically efficient. In the following years, allogeneic transplantation is likely to become more complex, more individualized, and more efficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.